298 reports of this reaction
1.9% of all RANOLAZINE reports
#10 most reported adverse reaction
CARDIAC DISORDER is the #10 most commonly reported adverse reaction for RANOLAZINE, manufactured by A2A Integrated Pharmaceuticals. There are 298 FDA adverse event reports linking RANOLAZINE to CARDIAC DISORDER. This represents approximately 1.9% of all 15,363 adverse event reports for this drug.
Patients taking RANOLAZINE who experience cardiac disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CARDIAC DISORDER is a less commonly reported adverse event for RANOLAZINE, but still significant enough to appear in the safety profile.
In addition to cardiac disorder, the following adverse reactions have been reported for RANOLAZINE:
The following drugs have also been linked to cardiac disorder in FDA adverse event reports:
CARDIAC DISORDER has been reported as an adverse event in 298 FDA reports for RANOLAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CARDIAC DISORDER accounts for approximately 1.9% of all adverse event reports for RANOLAZINE, making it a notable side effect.
If you experience cardiac disorder while taking RANOLAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.